Targeted treatments with anti-EGFR monoclonal antibodies (cetuximab and panitumumab) are recommended by the NCCN for metastatic CRC patients whose tumors do not harbour KRAS mutations [3, 4].The determination of the KRAS mutational status in CRC patients is essential for the management of CRC. The gene discussed is KRAS; the disease is colorectal carcinoma.